Jun-13-22 01:53PM | |
Jun-02-22 07:00AM | |
May-26-22 05:01PM | |
May-17-22 07:00AM | |
May-14-22 09:18AM | |
May-13-22 12:00AM | |
May-12-22 04:00PM | |
May-11-22 07:00AM | |
May-06-22 07:00AM | |
May-05-22 07:00AM | |
Apr-11-22 07:00AM | |
Apr-04-22 07:00AM | |
Mar-18-22 02:05PM | |
Mar-17-22 04:00PM | |
Mar-11-22 07:00AM | |
Mar-10-22 07:00AM | |
Mar-07-22 07:54AM | |
06:00AM | |
Feb-28-22 07:00AM | |
Feb-11-22 07:00AM | |
Feb-01-22 10:00AM | |
Jan-26-22 06:44PM | |
Jan-20-22 07:00AM | |
Jan-05-22 08:00AM | |
Jan-04-22 07:00AM | |
Dec-22-21 11:00AM | |
Dec-15-21 08:07AM | |
Dec-10-21 08:35AM | |
Dec-06-21 10:00AM | |
07:00AM | |
Dec-01-21 04:00PM | |
Nov-30-21 07:00AM | |
Nov-11-21 07:00AM | |
Nov-10-21 08:30PM | |
04:00PM | |
Nov-03-21 07:00AM | |
06:02AM | |
Nov-01-21 04:14PM | |
02:36PM | |
02:11PM | |
01:47PM | |
12:15PM | |
11:30AM | |
11:06AM | |
10:00AM | |
09:13AM | |
09:11AM | |
07:45AM | |
Oct-31-21 10:35AM | |
Oct-30-21 01:18PM | |
Oct-29-21 03:53PM | |
02:23PM | |
02:00PM | |
01:45PM | |
12:40PM | |
11:00AM | |
09:00AM | |
07:40AM | |
Oct-28-21 05:45PM | |
04:15PM | |
03:06PM | |
01:37PM | |
12:30PM | |
11:00AM | |
08:59AM | |
07:30AM | |
05:19AM | |
Oct-27-21 10:55PM | |
10:42PM | |
09:00PM | |
05:38PM | |
04:10PM | |
02:49PM | |
01:18PM | |
12:31PM | |
09:00AM | |
07:45AM | |
05:40AM | |
Oct-26-21 09:45PM | |
05:24PM | |
03:45PM | |
03:00PM | |
02:00PM | |
01:13PM | |
12:45PM | |
12:15PM | |
11:29AM | |
10:00AM | |
09:08AM | |
07:40AM | |
05:40AM | |
Oct-25-21 11:38PM | |
03:55PM | |
03:30PM | |
02:50PM | |
11:45AM | |
11:00AM | |
09:00AM | |
08:07AM | |
Oct-24-21 10:20AM | |
|
|
|
Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology and hematology drug products. The company's products under development include Eflapegrastim, a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia; Poziotinib, a novel irreversible tyrosine kinase inhibitor for non-small cell lung cancer tumors with various mutations; and Anti-CD20-IFNa, an antibody-interferon fusion molecule directed against CD20 that is in Phase I development for the treatment of patients with relapsed or refractory non-Hodgkin's lymphoma, including diffuse large B-cell lymphoma. It has co-development, commercialization, and in-license agreements with Hanmi Pharmaceutical Co. Ltd.; a patent and technology license agreement with The University of Texas M.D. Anderson Cancer Center; and in-license agreement with ImmunGene, Inc. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was incorporated in 1987 and is based in Henderson, Nevada. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
LEBEL FRANCOIS | Chief Medical Officer | Jun 23 | Sale | 0.84 | 6,667 | 5,594 | 644,790 | Jun 23 08:24 PM | LEBEL FRANCOIS | Chief Medical Officer | Jun 22 | Sale | 0.81 | 6,096 | 4,913 | 651,457 | Jun 23 08:24 PM | Brennan Nora | EVP & CFO | Jun 21 | Sale | 0.79 | 3,569 | 2,802 | 360,215 | Jun 23 07:56 PM | Vyas Dolatrai | Former Director | Jun 21 | Sale | 0.79 | 4,283 | 3,362 | 82,063 | Jun 22 09:45 PM | Ashton William | Director | Jun 21 | Sale | 0.79 | 4,283 | 3,362 | 42,660 | Jun 22 09:20 PM | Fischer Seth H. Z. | Director | Jun 21 | Sale | 0.79 | 5,711 | 4,483 | 29,066 | Jun 22 09:55 PM | LEBEL FRANCOIS | Chief Medical Officer | Apr 05 | Sale | 1.41 | 1,367 | 1,927 | 252,513 | Apr 05 05:42 PM | LEBEL FRANCOIS | Chief Medical Officer | Apr 04 | Sale | 1.35 | 1,205 | 1,627 | 253,880 | Apr 05 05:42 PM | GUSTAFSON KURT A | EVP & Chief Financial Officer | Mar 16 | Sale | 0.71 | 16,318 | 11,521 | 317,259 | Mar 16 06:15 PM | Riga Thomas J | CEO & President | Mar 16 | Sale | 0.71 | 18,829 | 13,293 | 568,800 | Mar 16 06:29 PM | McGahan Keith M | Chief Legal Officer | Mar 16 | Sale | 0.71 | 16,318 | 11,521 | 244,940 | Mar 16 06:39 PM | LEBEL FRANCOIS | Chief Medical Officer | Mar 16 | Sale | 0.71 | 25,105 | 17,724 | 255,085 | Mar 16 07:11 PM | LEBEL FRANCOIS | Chief Medical Officer | Mar 15 | Sale | 0.70 | 25,130 | 17,717 | 280,190 | Mar 16 07:11 PM | McGahan Keith M | Chief Legal Officer | Mar 15 | Sale | 0.70 | 14,658 | 10,334 | 261,258 | Mar 16 06:39 PM | Riga Thomas J | CEO & President | Mar 15 | Sale | 0.70 | 20,356 | 14,351 | 587,629 | Mar 16 06:29 PM | GUSTAFSON KURT A | EVP & Chief Financial Officer | Mar 15 | Sale | 0.70 | 20,653 | 14,560 | 333,577 | Mar 16 06:15 PM | McGahan Keith M | Chief Legal Officer | Feb 24 | Sale | 0.64 | 15,031 | 9,620 | 275,916 | Feb 24 07:21 PM | Riga Thomas J | CEO & President | Feb 24 | Sale | 0.64 | 18,441 | 11,802 | 607,985 | Feb 24 08:42 PM | LEBEL FRANCOIS | Chief Medical Officer | Feb 24 | Sale | 0.64 | 14,708 | 9,413 | 305,320 | Feb 24 09:04 PM | GUSTAFSON KURT A | EVP & Chief Financial Officer | Feb 24 | Sale | 0.64 | 15,958 | 10,213 | 354,230 | Feb 24 06:43 PM | GUSTAFSON KURT A | EVP & Chief Financial Officer | Feb 23 | Sale | 0.70 | 20,215 | 14,211 | 366,188 | Feb 24 06:43 PM | LEBEL FRANCOIS | Chief Medical Officer | Feb 23 | Sale | 0.70 | 13,466 | 9,467 | 320,028 | Feb 24 09:04 PM | Riga Thomas J | CEO & President | Feb 23 | Sale | 0.70 | 19,953 | 14,027 | 626,426 | Feb 24 08:42 PM | McGahan Keith M | Chief Legal Officer | Feb 23 | Sale | 0.70 | 13,513 | 9,500 | 290,947 | Feb 24 07:21 PM | LEBEL FRANCOIS | Chief Medical Officer | Nov 09 | Sale | 2.18 | 6,000 | 13,080 | 329,166 | Nov 10 08:32 PM | LEBEL FRANCOIS | Chief Medical Officer | Nov 08 | Sale | 2.20 | 7,363 | 16,221 | 335,166 | Nov 10 08:32 PM |
|